Brief: Tempest Announces First Patient Dosed In Randomized Study Evaluating TPST-1120
20/09/2021 13:16
Sept 20 (Reuters) - Tempest Therapeutics Inc TPST.O :
* TEMPEST ANNOUNCES FIRST PATIENT DOSED IN RANDOMIZED STUDY
EVALUATING TPST-1120 IN FIRST-LINE REGIMEN FOR HEPATOCELLULAR
CARCINOMA IN CLINICAL COLLABORATION WITH ROCHE
Source text for Eikon: ID:nGNX1lP9xX
Further company coverage: TPST.O
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T